Gemfibrozil

Generic Name
Gemfibrozil
Brand Names
Lopid
Drug Type
Small Molecule
Chemical Formula
C15H22O3
CAS Number
25812-30-0
Unique Ingredient Identifier
Q8X02027X3
Background

Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.

Gemfibrozil was granted FDA approval on 21 December 1981.

Indication

Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions. Gemfibrozil is also indicated to reduce the risk of developing coronary h...

Associated Conditions
Coronary Heart Disease (CHD), Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia
Associated Therapies
-
Clinical Trials
Related News

To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

First Posted Date
2010-03-09
Last Posted Date
2010-07-01
Lead Sponsor
AstraZeneca
Target Recruit Count
19
Registration Number
NCT01083212
Locations
🇸🇪

Reserach Site, Linkoping, Sweden

🇸🇪

Research Site, Uppsala, Sweden

Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil

First Posted Date
2007-12-04
Last Posted Date
2009-02-18
Lead Sponsor
Elixir Pharmaceuticals
Target Recruit Count
14
Registration Number
NCT00566865

Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil

Not Applicable
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Lopinavir/Ritonavir
Drug: Gemfibrozil
First Posted Date
2007-05-16
Last Posted Date
2016-09-26
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
15
Registration Number
NCT00474201
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

Phase 3
Completed
Conditions
Coronary Heart Disease
Interventions
Other: Placebo
Drug: gemfibrozil
First Posted Date
2006-01-27
Last Posted Date
2015-10-21
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
2531
Registration Number
NCT00283335
Locations
🇺🇸

Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States

Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques

Phase 4
Withdrawn
Conditions
Atherosclerosis
First Posted Date
2005-10-24
Last Posted Date
2007-11-19
Lead Sponsor
University Hospital Muenster
Target Recruit Count
100
Registration Number
NCT00243672

Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides

Phase 1
Completed
Conditions
Hypertriglyceridemia
First Posted Date
2005-04-18
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00108511
Locations
🇺🇸

Roudebush VA Medical Center, Indianapolis, Indiana, United States

Endothelial Dysfunction as a Risk Factor in HIV Study

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2002-06-07
Last Posted Date
2008-03-04
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
75
Registration Number
NCT00039663
Locations
🇺🇸

National Institutes of Health Clinical Center (CC), Bethesda, Maryland, United States

Harvard Atherosclerosis Reversibility Project (HARP)

First Posted Date
1999-10-28
Last Posted Date
2016-03-16
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000461
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy